These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1768 related articles for article (PubMed ID: 22727733)

  • 41. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib.
    Tsukui Y; Mochizuki H; Hoshino Y; Kawakami S; Kuno T; Fukasawa Y; Iwamoto F; Hirose S; Yoshida T; Hosoda K; Suzuki Y; Hosoda K; Kojima Y; Hirose Y; Shindou K; Matsuda M; Yagawa S; Tawara A; Kobayashi M; Konishi T; Yamazaki T; Takahashi S; Fuji H; Enomoto N; Omata M
    Hepatogastroenterology; 2012; 59(120):2536-9. PubMed ID: 22497953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
    Schmidt L; op den Winkel M; Fischer K; Straub G; Rauch B; Paprottka PM; Göke B; Kolligs FT
    Digestion; 2014; 90(4):219-28. PubMed ID: 25502689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Rimassa L; Santoro A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
    Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
    Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
    Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.
    Berretta M; Di Benedetto F; Dal Maso L; Cacopardo B; Nasti G; Facchini G; Bearz A; Spina M; Garlassi E; De Re V; Fiorica F; Lleshi A; Tirelli U
    Anticancer Drugs; 2013 Feb; 24(2):212-8. PubMed ID: 23197082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
    Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
    Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
    Song T; Zhang W; Wu Q; Kong D; Ma W
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Weintraub JL; Salem R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of sorafenib-related adverse events: a clinician's perspective.
    Brose MS; Frenette CT; Keefe SM; Stein SM
    Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
    Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
    Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
    Kim DY; Kim HJ; Han KH; Han SY; Heo J; Woo HY; Um SH; Kim YH; Kweon YO; Lim HY; Yoon JH; Lee WS; Lee BS; Lee HC; Ryoo BY; Yoon SK
    Cancer Res Treat; 2016 Oct; 48(4):1243-1252. PubMed ID: 26910470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 89.